PF 1163AAlternative Names: (-)-PF1163A
Latest Information Update: 04 Dec 2006
At a glance
- Originator Meiji Seika Kaisha
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 13 Dec 2002 Preclinical trials in Mycoses in Japan (unspecified route)
- 25 May 2000 Preclinical development for Mycoses in Japan (Unknown route)